Crux Wealth Advisors Has $861,000 Stock Position in Sanofi $SNY

Key Points

• Crux Wealth Advisors increased its stake in Sanofi by 60.1% during Q2, now holding 17,824 shares valued at approximately $861,000.
• Multiple hedge funds have recently acquired shares in Sanofi, with institutional investors owning 14.04% of the stock.
• Sanofi's shares received positive ratings from analysts, with a consensus rating of "Buy" and a target price of $62.67.

Crux Wealth Advisors boosted its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 60.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,824 shares of the company's stock after buying an additional 6,694 shares during the period. Crux Wealth Advisors' holdings in Sanofi were worth $861,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of SNY. Ameritas Advisory Services LLC acquired a new stake in shares of Sanofi during the second quarter valued at approximately $28,000. Accent Capital Management LLC purchased a new position in Sanofi during the 1st quarter worth approximately $29,000. Eastern Bank grew its position in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Sanofi during the 1st quarter valued at $33,000. Finally, Golden State Wealth Management LLC lifted its holdings in shares of Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on SNY shares. Morgan Stanley upgraded Sanofi from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $56.00 to $58.00 in a report on Monday, September 8th. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Weiss Ratings reiterated a "hold (c)" rating on shares of Sanofi in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a report on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $62.67.

Sanofi Stock Up 1.2%

Shares of Sanofi stock opened at $50.62 on Friday. The firm has a market cap of $124.30 billion, a price-to-earnings ratio of 12.17, a P/E/G ratio of 1.23 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The stock has a 50-day simple moving average of $48.49 and a 200-day simple moving average of $49.60.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company's quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.73 EPS. On average, equities research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.